**eFigure 1: Impacts of each 10% increment of tumor-infiltrating lymphocytes on overall survival in Luminal subtype.**



**eFigure 2: Impacts of each 10% increment of tumor-infiltrating lymphocytes on overall survival in HER2-overexpression subtype.**



**eFigure 3: Impacts of each 10% increment of tumor-infiltrating lymphocytes on overall survival in triple-negative subtype.**



**eFigure 4: Impacts of the high-level TILs on the pathological completed response in different tumor subtypes.**



**eTable 1. Publication bias by Egg’s test in meta-analysis.**

|  |  |
| --- | --- |
| **Analysis label** | **p value\*** |
| *10% increment of TILs* | 　 |
| OS in all subtype | 0.192  |
| OS in Luminal subtype | 0.437  |
| OS in HER2-enriched subtype | 0.536  |
| OS in TN subtype | 0.001  |
| pCR in all subtype | 0.303  |
| *High-level TILs* |  |
| pCR in all subtype | 0.007  |
| pCR in Luminal subtype | 0.745 |
| pCR in HER2-enriched subtype | 0.379 |
| pCR in TN subtype | 0.775 |
| *High-level TILs*  |  |
| HER2-enriched vs Luminal | 0.115  |
| TNBC vs Luminal  | 0.680  |
| TNBC vs HER2-enriched | 0.350  |

\*significant level p<0.1.

Abbreviations: TILs, tumor-infiltrating lymphocytes; OS, overall survival; pCR, pathological complete response; HER2, human epidermal growth factor receptor 2; TN, triple-negative.

**eFigure 5. Funnel plots for the significant analyses of publication bias.**



A. 10% increment of TILs and OS in TN subtype; B. High-level TILs and pCR in all subtypes